US10759721B2ActiveUtilityA1

Deuterated CFTR potentiators

92
Assignee: VERTEX PHARMACEUTICALS EUROPE LTDPriority: Sep 25, 2015Filed: Sep 23, 2016Granted: Sep 1, 2020
Est. expirySep 25, 2035(~9.2 yrs left)· nominal 20-yr term from priority
Inventors:Adam J. MorganRoger D. Tung
C07B 49/00A61P 11/12C07D 215/56
92
PatentIndex Score
5
Cited by
195
References
1
Claims

Abstract

This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

Claims

exact text as granted — not AI-modified
We claim: 
     
       1. A process for the synthesis of compound 28: 
       
         
           
           
               
               
           
         
         comprising converting compound 27: 
       
       
         
           
           
               
               
           
         
         into compound 28 in the presence of —CD 3 MgI, diethyl ether, and THF.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.